| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 2.03M | 122K | 183K |
| Revenue Growth % | - | -0.94% | 0.5% |
| Cost of Goods Sold | 0 | 0 | 665K |
| COGS % of Revenue | - | - | 3.63% |
| Gross Profit | 2.03M | 122K | -482K |
| Gross Margin % | 1% | 1% | -2.63% |
| Gross Profit Growth % | - | -0.94% | -4.95% |
| Operating Expenses | 18.71M | 11.87M | 9.44M |
| OpEx % of Revenue | 9.22% | 97.28% | 51.58% |
| Selling, General & Admin | 8.96M | 7.6M | 7.12M |
| SG&A % of Revenue | 4.42% | 62.31% | 38.91% |
| Research & Development | 9.75M | 4.27M | 2.98M |
| R&D % of Revenue | 4.81% | 34.97% | 16.3% |
| Other Operating Expenses | 0 | 0 | -665K |
| Operating Income | -16.68M | -11.75M | -9.92M |
| Operating Margin % | -8.22% | -96.28% | -54.21% |
| Operating Income Growth % | - | 0.3% | 0.16% |
| EBITDA | -15.83M | -10.71M | -9.26M |
| EBITDA Margin % | -7.8% | -87.82% | -50.58% |
| EBITDA Growth % | - | 0.32% | 0.14% |
| D&A (Non-Cash Add-back) | 856K | 1.03M | 665K |
| EBIT | -16.64M | -11.68M | -6.84M |
| Net Interest Income | -200K | 40K | -378K |
| Interest Income | 48K | 63K | 9K |
| Interest Expense | 248K | 23K | 387K |
| Other Income/Expense | -200K | 40K | 2.69M |
| Pretax Income | -16.89M | -11.71M | -7.23M |
| Pretax Margin % | -8.32% | -95.95% | -39.52% |
| Income Tax | 330K | 0 | 0 |
| Effective Tax Rate % | 1.02% | 1% | 1% |
| Net Income | -17.21M | -11.71M | -7.23M |
| Net Margin % | -8.48% | -95.95% | -39.52% |
| Net Income Growth % | - | 0.32% | 0.38% |
| Net Income (Continuing) | -17.21M | -11.71M | -7.23M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 549K | 549K | 549K |
| EPS (Diluted) | -0.46 | -0.72 | -0.74 |
| EPS Growth % | - | -0.57% | -0.03% |
| EPS (Basic) | -0.46 | -0.72 | -0.74 |
| Diluted Shares Outstanding | 37.5M | 16.19M | 23.41M |
| Basic Shares Outstanding | 37.5M | 16.19M | 23.41M |
| Dividend Payout Ratio | - | - | - |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 9.65M | 2.04M | 3.78M |
| Cash & Short-Term Investments | 7.33M | 723K | 2.85M |
| Cash Only | 7.33M | 723K | 2.85M |
| Short-Term Investments | 0 | 0 | 0 |
| Accounts Receivable | 2.03M | 88K | 323K |
| Days Sales Outstanding | 365.18 | 263.28 | 644.24 |
| Inventory | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 292K | 1.22M | 603K |
| Total Non-Current Assets | 2.21M | 1.32M | 885K |
| Property, Plant & Equipment | 1.8M | 1.07M | 455K |
| Fixed Asset Turnover | 1.13x | 0.11x | 0.40x |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 196K | 186K | 176K |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 207K | 66K | 254K |
| Total Assets | 11.85M | 3.35M | 4.66M |
| Asset Turnover | 0.17x | 0.04x | 0.04x |
| Asset Growth % | - | -0.72% | 0.39% |
| Total Current Liabilities | 10.87M | 15.74M | 19.61M |
| Accounts Payable | 8.15M | 7.92M | 3.94M |
| Days Payables Outstanding | - | - | 2.16K |
| Short-Term Debt | 0 | 1.74M | 2.87M |
| Deferred Revenue (Current) | 64K | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 80K |
| Current Ratio | 0.89x | 0.13x | 0.19x |
| Quick Ratio | 0.89x | 0.13x | 0.19x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 76.72M | 76.05M | 0 |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 1.12M | 455K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 75.6M | 75.6M | 0 |
| Total Liabilities | 87.59M | 91.79M | 19.61M |
| Total Debt | 1.87M | 2.89M | 3.33M |
| Net Debt | -5.45M | 2.17M | 478K |
| Debt / Equity | - | - | - |
| Debt / EBITDA | - | - | - |
| Net Debt / EBITDA | - | - | - |
| Interest Coverage | -67.28x | -510.70x | -25.64x |
| Total Equity | -75.73M | -88.44M | -14.95M |
| Equity Growth % | - | -0.17% | 0.83% |
| Book Value per Share | -2.02 | -5.46 | -0.64 |
| Total Shareholders' Equity | -76.28M | -88.98M | -15.49M |
| Common Stock | 9K | 2K | 5K |
| Retained Earnings | -93.86M | -108.87M | -116.1M |
| Treasury Stock | -33K | -33K | 0 |
| Accumulated OCI | 0 | 0 | 0 |
| Minority Interest | 549K | 549K | 549K |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -8.95M | -7.4M | -9.03M |
| Operating CF Margin % | -4.41% | -60.67% | -49.34% |
| Operating CF Growth % | - | 0.17% | -0.22% |
| Net Income | -17.21M | -11.71M | -7.23M |
| Depreciation & Amortization | 856K | 792K | 622K |
| Stock-Based Compensation | 4.02M | 2.31M | 1.93M |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 0 | -3.03M |
| Working Capital Changes | 3.39M | 1.21M | -1.32M |
| Change in Receivables | -1.99M | 1.95M | -235K |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 6.24M | -743K | -860K |
| Cash from Investing | -65K | -48K | 0 |
| Capital Expenditures | -65K | -48K | 0 |
| CapEx % of Revenue | 0.03% | 0.39% | - |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | 331.52K | 0 | 0 |
| Cash from Financing | 9.78M | 849K | 11.16M |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | -743.83K | -371K | -2.09M |
| Net Change in Cash | - | - | - |
| Free Cash Flow | -9.02M | -7.45M | -9.03M |
| FCF Margin % | -4.44% | -61.07% | -49.34% |
| FCF Growth % | - | 0.17% | -0.21% |
| FCF per Share | -0.24 | -0.46 | -0.39 |
| FCF Conversion (FCF/Net Income) | 0.52x | 0.63x | 1.25x |
| Interest Paid | 30K | 16K | 1K |
| Taxes Paid | 0 | 0 | 0 |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Gross Margin | 100% | 100% | -263.39% |
| Net Margin | -848.45% | -9595.08% | -3951.91% |
| Interest Coverage | -67.28x | -510.70x | -25.64x |
| FCF Conversion | 0.52x | 0.63x | 1.25x |
| Revenue Growth | - | -93.99% | 50% |
Abpro Holdings Inc (ABPWW) reported $0.2M in revenue for fiscal year 2024. This represents a 91% decrease from $2.0M in 2022.
Abpro Holdings Inc (ABPWW) grew revenue by 50.0% over the past year. This is strong growth.
Abpro Holdings Inc (ABPWW) reported a net loss of $12.7M for fiscal year 2024.
Abpro Holdings Inc (ABPWW) had negative free cash flow of $7.9M in fiscal year 2024, likely due to heavy capital investments.